首页> 外文期刊>Indian drugs >DESIGN AND EVALUATION OF RECONSTITUTABLE ORAL SUSPENSION CONTAINING DELAYED RELEASE PANTOPRAZOLE MICROSPHERES
【24h】

DESIGN AND EVALUATION OF RECONSTITUTABLE ORAL SUSPENSION CONTAINING DELAYED RELEASE PANTOPRAZOLE MICROSPHERES

机译:含缓释泛PR唑微球的可复口服混悬液的设计与评价

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the min present study was to develop pantoprazole suspension containing delayed release (DR) microspheres to target the drug release intestine. This study is divided into two sections, first one is to prepare DR pantoprazole microspheres and second is to formulate into reconstitutional oral suspension. Quality by Design (QbD) approach was used in the study. Polymethacrylate (Eudragit L100-55) was used for the development of delayed release microspheres. To prepare reconstitutional suspension formulation, 90% particle size of microspheres less than 50 microns and with 90% loading efficiency was used. Xanthan gum is used as suspending agent and D-mannitol is used as sweetening agent. FTIR study shows compatibility of the drug with polymer. Moreover, the same release rate of pantoprazole from the suspension and microspheres alone indicated that the suspension medium studied did not affect the property of drug release during storage.
机译:本研究的最小目的是开发含有延迟释放(DR)微球的pan托拉唑混悬液,以靶向药物释放肠。这项研究分为两个部分,第一部分是制备DR潘托拉唑微球,第二部分是配制为重组口服混悬剂。研究中使用了设计质量(QbD)方法。聚甲基丙烯酸酯(Eudragit L100-55)用于开发缓释微球。为了制备复原悬浮液制剂,使用了小于50微米且装载效率为90%的90%的微球粒径。黄原胶用作悬浮剂,D-甘露醇用作甜味剂。 FTIR研究表明该药物与聚合物具有相容性。此外,pan托拉唑仅从悬浮液和微球中的释放速率相同,这表明所研究的悬浮介质不会影响药物在储存过程中的释放性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号